Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

5 C
Cheshire
Sunday, April 6, 2025

Esteve Enters The American Pain Market With Its New Medicine

The Spanish company Esteve has obtained approval from the American FDA for its new treatment, Seglentis, indicated for the treatment of acute pain in adults. The total market for this therapeutic area in the United States is between 1,000 and 1,500 million euros.

The drug is Esteve’s first own research product to be marketed across the Atlantic. The Spanish company will rely on the pharmaceutical company Kowa to market the drug in the United States. In addition to the royalties the drug provides through its sales, the company will also receive regulatory milestone payments. The agreement, according to the company agreed to this medium, is long-term.

This move comes as the company is also working on marketing the drug in Europe. Esteve is pending to receive the approval of the European Medicines Agency, but also accelerates with some countries to try to shorten the deadlines. Negotiations with Spain, Italy and Portugal are currently open.

Seglentis is an innovative medicine, the first of its kind, composed of a cocrystalline form of celecoxib (anti-inflammatory) and tramadol (pain reliever). The company stresses that the drug offers a new acute pain treatment option aligned with multimodal analgesia, currently considered the standard of care for pain control.

Staffan Schüberg, CEO of the Spanish pharmaceutical company, declared that they are “very proud of this achievement, as it is recognition of our daily efforts to meet the needs of patients and address the current challenges of treating acute pain.”

spot_imgspot_img

Latest

Planning consent granted in Congleton for McGoff Group

The McGoff Group has received planning permission for a...

Tooltap Launches in Manchester to Bring Equipment Sharing to Local Communities

Manchester-based platform is making it easier for residents to...

Enviro Waste Management Rebrands to Champion Business-Focused Waste Solutions

Enviro Waste Management has revealed a fresh brand identity...

ECB Intraday Liquidity Framework Offers Direction—But Practical Compliance Still a Major Challenge

The European Central Bank’s (ECB) newly established intraday liquidity...
spot_imgspot_img

Newsletter

Don't miss

Thousands Risk Losing Personalised Number Plates as DVLA Enforcement Tightens

A growing number of private number plate holders across...

£10,000 reward to identify mother of baby found in Kirkham brook

Crimestoppers is offering a reward of up to £10,000...

ECB Intraday Liquidity Framework Offers Direction—But Practical Compliance Still a Major Challenge

The European Central Bank’s (ECB) newly established intraday liquidity...

Tooltap Launches in Manchester to Bring Equipment Sharing to Local Communities

Manchester-based platform is making it easier for residents to...

More News

Crewe Hall Hotel & Spa crowned ‘Wedding Venue of the Year’

Crewe Hall Hotel & Spa has been named Wedding Venue of the Year at the Marketing Cheshire Tourism Awards. The awards celebrate the excellence and outstanding...

Time to Talk Day – top tips on discussing mental health

Tomorrow (February 6) is 'Time to Talk Day'. Talking about mental health can feel uncomfortable, but it’s one of the most powerful ways to break...

From Carl Icahn to Yuri Milner: Five Billionaire Investors Who Have Joined the Giving Pledge

As of March 2024, Warren Buffett is the world’s richest billionaire investor, with a net worth of $133.8 billion. The Berkshire Hathaway founder is...